$885 Million is the total value of Spyglass Capital Management LLC's 25 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EVBG | Sell | EVERBRIDGE INC | $32,566,000 | +23.5% | 306,184 | -9.3% | 3.68% | +8.7% |
| EQIX | Sell | EQUINIX INC | $22,275,000 | +0.3% | 35,665 | -6.3% | 2.52% | -11.8% |
| DXCM | Sell | DEXCOM INC | $18,441,000 | -23.4% | 68,485 | -37.8% | 2.08% | -32.6% |
| IMAX | Exit | IMAX CORP | $0 | – | -636,478 | -100.0% | -1.67% | – |
| AMD | Exit | ADVANCED MICRO DEVICES INC | $0 | – | -606,288 | -100.0% | -3.57% | – |
| PWR | Exit | QUANTA SVCS INC | $0 | – | -830,843 | -100.0% | -4.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PALO ALTO NETWORKS INC | 20 | Q3 2023 | 7.1% |
| NUTANIX INC CL A | 20 | Q3 2023 | 5.9% |
| GODADDY INC CL A | 20 | Q3 2023 | 5.5% |
| SPLUNK INC | 20 | Q3 2023 | 7.2% |
| EXACT SCIENCES CORP | 20 | Q3 2023 | 5.7% |
| ASCENDIS PHARMA AS SPONSORED ADR | 20 | Q3 2023 | 7.0% |
| AFFILIATED MANAGERS GROUP INC | 20 | Q3 2023 | 6.4% |
| PACIRA PHARMACEUTICALS INC | 18 | Q1 2023 | 5.2% |
| VAIL RESORTS INC | 17 | Q3 2023 | 4.4% |
| ULTA BEAUTY INC | 15 | Q2 2022 | 5.5% |
View Spyglass Capital Management LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2022-11-14 |
| SC 13G/A | 2022-11-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Spyglass Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.